Abstract:Alzheimer's disease (AD) is the most common neurodegenerative disorders now. Amyloid ß-protein (Aß) has been recognized as the leading cause of AD, and Aß oligomer plays an important role in the early stage of AD. Anti-Ab immunotherapy targeting on the Ab peptide has been demonstrated as one promising AD treatment. The active immunization, exploiting Ab42 as an immunogen, was initiated on AD animal model by Schenk in 1999 and then advanced to clinical trials. However, the clinical trial was haunted due to an occurrence of subacute meningoencephalitis in 6% of patients. Th1-biased responses stimulated by T cell epitope in the Ab42 and Th1-promoting adjuvant (QS-21) were ascribed to this side effect. Meanwhile, anti-Ab antibodies produced in those patients have been proved to be effective in slowering rate of cognitive decline. As an alternative, passive immunization approaches have the advantage of safety and efficacy over active immunization approaches. In this report, several strains of monoclonal antibody (MAb) against Aß1-42 oligomer or different truncation of Aß C terminal was established for AD therapeutic research. MAb specific for Aß1-42 oligomer was prepared with the hybridoma technique and purified through protein A affinity chromatography. The specificity, affinity and titers of the MAb were analyzed by ELISA, western blot and immunohistochemistry (IHC). To determine whether Antibodies treatment improves the ability of learning and memory, 8-month-old SAMP8 mice and 6-month-old APPswe/PS1DE9 mice were administered intraperitoneally and weekly with 400 mg A8 or nonspecific mouse IgG (Sigma-Aldrich) for 8 weeks. The Morris water maze (MWM) has been used for studying therapy-related changes in learning and memory in mice. The visible, hidden versions of MWM and prob trial were performed. The latency and distance to find the location that had contained the platform was measured. Data were recorded through an overhead camera linked with the computer to quantification of latency and distance. Mice were tested in a blinded manner, with group balanced for genotype and treatment. Mice were sacrificed 3 days after the final MWM manipulation for biochemical and histological assessment. Through western blot (WB) and immunohistochemistry (IHC), the soluble and insoluble Aß, phosphorylation of tau at 181/231/404 site, mTOR (mammalian target of rapamycin), LC3-I/II (microtubuler associated protein 1 light chain 3, MAP1rLC3, LC3), glial fibrillary acidic protein (GFAP), tubulin and actin were detected. Our results showed that the mice serum titer reached over 1:256,000 after immunization. Two hybridoma cell lines (BJ08 and BJNa) secreting MAb specific for the Aß1-42 oligomer was established after sub-cloning. They displayed much higher affinity to low molecular Aß1-42 oligomer, and showed the ability to bind Aß1-42 oligomer in the brain section of SAMP8 mice and APPswe/PS1DE9 mice. Using them as immunotherapy, we show that learning and memory ability was improved through intraperitoneal administration in SAMP8 mice. The mice that found the platform increased in antibody treated groups and our data showed a significant decrease in latency and distance compared with other groups (P < 0.05) (nonspecific mouse IgG, antibody solution buffer and no-treated SAMP8 or APPswe/PS1DE9 mice). Meanwhile, soluble Aß, phosphorylation of tau and LC3-II has also been inhibited after immunotherapy. In addition, the expression level of mTOR, GFAP, tubulin and actin were also detected with IHC and displayed no differences among these groups. In conclusion, the MAbs specific for Aß1-42 oligomer is developed. Therapeutic monoclonal antibodies against Aß oligomers have the efficacy in reducing soluble Aß, phosphorylation of tau and LC3-II level and ultimately ameliorated the learning and memory ability, which paves the way for further diagnostic and therapeutic research on AD.

An acute functional screen identifies an effective antibody targeting amyloid-β oligomers based on calcium imaging

An in Vitro Paradigm to Assess Potential Anti-Aβ Antibodies for Alzheimer’s Disease

Learnings about Aβ from Human Brain Recommend the Use of a Live-Neuron Bioassay for the Discovery of Next Generation Alzheimer’s Disease Immunotherapeutics

An enzyme-linked immunosorbent assay to compare the affinity of chemical compounds for β-amyloid peptide as a monomer

Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers.

TARGETING OF TOXIC AMYLOID-BETA OLIGOMER SPECIES BY MONOCLONAL ANTIBODY PMN310: PRECISION DRUG DESIGN FOR ALZHEIMER’S DISEASE

An Enzyme-Linked Immunosorbent Assay To Compare The Affinity Of Chemical Compounds For Beta-Amyloid Peptide As A Monomer

A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers.

SELECTIVE TARGETING OF AMYLOID-BETA OLIGOMER SPECIES BY PMN310, A MONOCLONAL ANTIBODY RATIONALLY DESIGNED FOR GREATER THERAPEUTIC POTENCY IN ALZHEIMER’S DISEASE

Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies

A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease

Selective Targeting and Protection Against Toxic Amyloid‐beta Oligomers by PMN310, a Monoclonal Antibody Rationally Designed for Greater Therapeutic Potency in Alzheimer’s Disease

Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat

PROPAGATIVE TOXIC Aβ OLIGOMER SUBCLASS IDENTIFIED AND DEFINED BY SOLVENT ORIENTATION OF THE LYSINE 28 SIDE CHAIN

An Overview of Several Inhibitors for Alzheimer's Disease: Characterization and Failure

Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease

Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo-PrPC binding and downstream pathways

Surface plasmon resonance biosensors for simultaneous monitoring of amyloid-beta oligomers and fibrils and screening of select modulators.

Therapeutic Monoclonal Antibodies Against Abeta Oligomers for Treatment of Alzheimer's Disease

Real-time monitoring of the amyloid β1-42 monomer-to-oligomer channel transition using a lipid bilayer system

Development and Implementation of a High-Throughput Compound Screening Assay for Targeting Disrupted ER Calcium Homeostasis in Alzheimer's Disease